Therapeutic Effect of Crizotinib for Rearrangement-negative, High Phosphorylated ALK Patients

NCT05792644 · clinicaltrials.gov ↗
NA
Phase
COMPLETED
Status
15
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Harbin Medical University